Abstract
During 2020 and 2021, the global pandemic of coronavirus disease 2019 (COVID-19) due to severe acute respi- ratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in high death rates and acute and chronic morbidity in all countries. The rapid development of new mRNA vaccines to SARS-CoV-2 brings hope that the spread of this virus can be controlled. The ChAdOx1 nCoV-19 vaccine developed by a collaboration between the University of Oxford and AstraZeneca showed efficacy in clinical trials, with a good safety profile. However, there have been recent reports of the rare development of thrombotic events in young women following vaccination with ChAdOx1 nCoV-19, particularly of the rare condition of cavernous sinus thrombosis. Studies have begun to in- vestigate whether antibodies to the SARS-CoV-2 spike cross-react with platelet factor 4 (PF4/CXLC4) and mim- ic autoimmune heparin-induced thrombocytopenia. This Medical Science Monitor Editorial aims to briefly update the current status of studies on a possible rare complication of using new mRNA vaccines to prevent COVID-19.
【초록키워드】 COVID-19, coronavirus disease, SARS-CoV-2, Coronavirus disease 2019, Efficacy, coronavirus, vaccination, thrombosis, antibody, mRNA vaccine, clinical trials, heparin, virus, global pandemic, Spread, morbidity, Platelet, Autoimmune, thrombocytopenia, women, Thrombotic events, ChAdOx1, collaboration, platelet factor 4, safety profile, AstraZeneca, ChAdOx1 nCoV-19, ChAdOx1 nCoV-19 vaccine, SARS-CoV-2 spike, Hope, Sinus thrombosis, heparin-induced thrombocytopenia, death rate, Science, cavernous sinus thrombosis, Oxford, syndrome, thrombotic, cavernous sinus, editorial, Prevent, thrombotic event, cross-react, the SARS-CoV-2, University of Oxford, 【제목키워드】 SARS-CoV-2, mRNA,